Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
everolimus + erlotinib
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A fixed regimen combination of the mTOR inhibitor everolimus and the EGFR tyrosine kinase inhibitor erlotinib, investigated as an oral targeted therapy for advanced solid tumors, notably non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC). Everolimus inhibits mTOR complex 1 signaling downstream of PI3K/AKT, while erlotinib inhibits EGFR tyrosine kinase; the dual blockade aims to overcome or delay resistance to EGFR inhibition by suppressing downstream pathway activation.[1][2][3][4][5]
- Brand names
- Afinitor + Tarceva
- Other names
- RAD001 + E
02
Targets
Mechanistic target of rapamycin complex 1EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on everolimus + erlotinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on everolimus + erlotinib.